Connect breast examination, imaging, and pathology to distinguish benign, in situ, and invasive lesions and choose risk-aware diagnostic and treatment steps.
A mobile mass can still need biopsy, an alarming scar can be benign, and an in situ diagnosis does not mean every patient needs the same operation. Breast assessment works when the examination, imaging, and tissue findings explain one another. Start by deciding what the patient actually has, then use invasion, subtype, extent, and biomarkers to guide the next decision.
Make the clinical finding and the tests agree
Describe a palpable lesion by its location, size, mobility, consistency, tenderness, growth, and associated skin, nipple, or nodal changes. A hard irregular fixed mass increases suspicion, while a smooth mobile lesion often has a benign cause. Neither pattern supplies a final diagnosis. A new persistent dominant mass requires diagnostic assessment rather than waiting for the next screening examination. Record pregnancy or lactation, prior procedures or trauma, medications, and hereditary risk because they change interpretation and test selection.
For a palpable mass in a patient younger than 30, targeted ultrasound is usually the initial study. From 30 to 39, ultrasound and diagnostic mammography or tomosynthesis are appropriate options depending on context. At 40 or older, diagnostic mammography or tomosynthesis usually begins the evaluation, with targeted ultrasound as needed. Pregnancy generally favors ultrasound first, but necessary diagnostic mammography should not be withheld simply because the patient is pregnant. Screening and diagnostic imaging answer different questions. [1][16]
BI-RADS is an assessment with an associated action, not a histologic diagnosis. Category 0 needs additional evaluation, 1 is negative, and 2 is benign. Category 3 means probably benign, with a malignancy probability no greater than about 2%, and often leads to short-interval imaging beginning around six months when findings are concordant. Categories 4 and 5 generally require tissue diagnosis; 6 denotes known biopsy-proven malignancy. A clinically suspicious mass cannot be dismissed solely because imaging is negative or a sample reports benign tissue. [2]
Core biopsy preserves architecture and permits assessment of invasion and biomarkers. After sampling, ask whether the tissue explains the targeted abnormality. A benign result from a spiculated suspicious mass may be discordant and require repeat biopsy or excision. Conversely, a biopsy-proven fibroadenoma that fully explains a stable, circumscribed lesion may be observed. The important endpoint is diagnostic concordance, not simply obtaining any benign pathology word. [3][19]
Distinguish fluid, fibroepithelial growth, and reactive tissue
A simple cyst is a fluid lesion with characteristic ultrasound findings, including anechoic contents, a thin wall, and posterior acoustic enhancement. Diffuse cyclic tenderness and nodularity often reflect fibrocystic changes. Nonproliferative changes do not carry the same future cancer risk as atypical hyperplasia. Proliferative disease without atypia may modestly increase risk; atypia requires its own risk and sampling assessment. Symptom relief is individualized, and hormonal medication is not compulsory for every cyclic complaint. [5]
A fibroadenoma is a benign biphasic epithelial and stromal lesion, often smooth and mobile in a younger patient and responsive to hormonal conditions. The 2025 ASBrS/SBI guidance supports observation for core-biopsy-proven concordant fibroadenomas without atypia unless symptoms, substantial growth, size, or patient preference justify excision. A universal 3-cm rule is too rigid. When a proven concordant lesion is observed, follow-up should match the guideline and clinical context rather than automatically imposing endless six-month imaging. [3]
Phyllodes tumors are also fibroepithelial, but their neoplastic stromal component produces a leaflike architecture and may grow rapidly. Grade depends on several features, including stromal cellularity, atypia, mitoses, overgrowth, and the border; one mitotic count alone does not settle every case. A suspicious fibroepithelial core often needs excision to classify the whole lesion. Complete excision is the goal for benign phyllodes, without a universal 1-cm margin mandate. Borderline and malignant tumors need specialist margin planning. Malignant spread is more often hematogenous than nodal, so routine axillary surgery is not automatic. [3]
Fat necrosis may follow trauma, surgery, or radiation, but a patient may recall none. Lipid release provokes macrophages, giant cells, and fibrosis. An oil cyst with rim calcification can be characteristic; an irregular spiculated or shadowing lesion can mimic carcinoma and require biopsy. A trauma history is supporting context, not a test that excludes cancer. [5]
An intraductal papilloma contains epithelial tissue around fibrovascular cores. A central lesion can cause spontaneous unilateral single-duct bloody or serous discharge, sometimes without an obvious mass on mammography. Such discharge still needs evaluation. Selected asymptomatic concordant papillomas without atypia may be observed, whereas symptoms, atypia, or discordance can favor excision. “Every papilloma must be excised” loses this distinction. [4]
Find the basement membrane before assigning invasion
Three different meanings of abnormal epithelial growth
Ductal carcinoma in situ Abnormal ductal cells remain within the duct-lobular system, bounded by the myoepithelial layer and basement membrane. Necrosis inside the duct does not itself prove invasion.
Classic lobular carcinoma in situ Dyshesive cells expand lobular units without stromal invasion. It signals bilateral future risk and can also be a nonobligate precursor.
Invasive carcinoma Malignant epithelial cells extend beyond the enclosing unit into stroma. Architecture then helps identify no-special-type, lobular, or another pattern.
Cell location establishes in situ versus invasive disease. Adhesion staining and necrosis describe other features and cannot replace that boundary assessment.
DCIS is often detected through calcifications, but can also present with a mass or discharge. Comedonecrosis is central necrosis in involved ducts and commonly accompanies high-grade disease. It is not synonymous with basement membrane penetration. Treatment considers extent, grade, margins, patient factors, and preferences. Breast-conserving surgery commonly includes radiation; mastectomy may be appropriate for extensive disease, and endocrine therapy can reduce subsequent breast events in ER-positive disease. Selected radiation omission is a risk discussion, not a rule that all low-grade DCIS needs no treatment. A single fixed progression percentage cannot describe every untreated lesion. [6]
Classic LCIS is both a marker of increased risk in either breast and a potential precursor; calling it “only a marker” is incomplete. The 2026 ASBrS/SBI/CAP guidance supports observation of classic LCIS or atypical lobular hyperplasia when pathology and imaging agree, together with comprehensive risk assessment. Pleomorphic and florid LCIS usually require diagnostic excision with negative margins. Calcifications can occur, particularly with variants, so “LCIS never appears on imaging” is false. Most ADH on core biopsy is excised to assess for an unsampled higher-grade lesion, although selected concordant cases can be observed after multidisciplinary review. [7]
E-cadherin is an adhesion protein. Loss commonly supports lobular differentiation, but staining is not an infallible standalone classifier and does not establish whether invasion is present. Read morphology and the tissue boundary alongside the immunostain. An LCIS diagnosis and an invasive lobular diagnosis can share adhesion loss while carrying different immediate management implications. [8]
Let architecture explain the physical finding
Invasive carcinoma of no special type, historically called invasive ductal carcinoma, is the most common invasive category. Malignant nests or glands within a desmoplastic stroma can produce a hard mass, architectural distortion, or skin tethering. Invasive lobular carcinoma often infiltrates as dyshesive single files and may produce subtle thickening rather than a discrete mass. Mammographic detection can be difficult. Additional imaging such as MRI is selected for the diagnostic or extent question, not substituted routinely for all other imaging. Lobular cancers have associations with multifocal or bilateral disease and spread to sites such as peritoneum, gastrointestinal tract, and ovaries, but those patterns are not obligatory in each patient. [8][9]
Mucinous carcinoma has tumor cells in extracellular mucin pools. A signet-ring cell instead contains intracellular mucin displacing its nucleus; that description can occur in lobular carcinoma and requires the complete histologic context. Tubular carcinoma forms well-developed small angulated tubules and often has favorable low-grade features. Neither favorable morphology nor a small size removes the need to determine stage and biomarkers. [8]
The older term medullary carcinoma is now generally classified as invasive carcinoma of no special type with a medullary pattern. Sheets of high-grade cells with prominent lymphoplasmacytic infiltration can have a relatively favorable association compared with otherwise similar high-grade cancers, and the pattern is associated with BRCA1. Lymphocytes do not form a reliable wall that makes the tumor noninvasive or guarantees a good outcome. Classification and prognosis should not be reduced to that visual metaphor. [8]
Do not require a lump before considering malignancy
Persistent unilateral nipple eczema, erosion, or crusting can be Paget disease. Biopsy the nipple lesion and investigate the breast for underlying DCIS or invasive carcinoma. A normal mammogram does not end the evaluation when the nipple finding remains suspicious. Most cases have an associated underlying carcinoma, but “always” is too strong. Temporary improvement with a topical steroid does not prove a persistent unilateral nipple process is harmless eczema. [10]
Inflammatory breast cancer presents rapidly with erythema, warmth, edema, or peau d'orange involving a substantial portion of the breast, classically at least one-third. It may occur without a discrete mass. Tumor obstruction of dermal lymphatics explains the skin changes, but dermal lymphatic emboli are not found in every skin biopsy and their absence does not alone exclude the clinical diagnosis. Confirm invasive carcinoma with appropriate tissue sampling and stage the disease. It is stage III or IV at diagnosis, not one universal stage. For nonmetastatic disease, systemic treatment usually precedes mastectomy and radiation. Persistent presumed mastitis needs reassessment, including during lactation. [11][12]
Bilateral milky multiduct discharge suggests a different process from spontaneous unilateral bloody discharge. Review pregnancy status, prolactin, thyroid and renal function when indicated, and medications. Metoclopramide blocks dopamine D2 receptors and can increase prolactin, causing galactorrhea. Domperidone also blocks dopamine receptors; it is not a prolactin-sparing substitution. [18] Medication review does not replace assessment of a separate focal mass or pathologic discharge. [13]
Combine biology, extent, and inherited risk
Invasive cancer testing includes ER, PR, and HER2. For DCIS, ER testing informs endocrine risk reduction; do not indiscriminately apply every invasive-cancer biomarker decision to every benign or in situ lesion. ER-positive invasive disease generally benefits from endocrine therapy, but ER positivity and negative nodes do not automatically eliminate chemotherapy. Clinical risk and, in appropriate populations, validated genomic assays help that decision. Premenopausal endocrine options include tamoxifen or an aromatase inhibitor with ovarian suppression; an aromatase inhibitor alone is not the usual effective premenopausal strategy. [6]
HER2 overexpression or amplification supports conventional HER2-directed regimens such as trastuzumab, with appropriate cardiac monitoring. HER2-low eligibility for certain antibody-drug conjugates in advanced disease is a separate indication, not proof that standard trastuzumab benefits every HER2-low tumor. Triple-negative disease lacks ER, PR, and HER2 targets but still has systemic options. High-risk early-stage TNBC can receive pembrolizumab with neoadjuvant chemotherapy followed by postoperative pembrolizumab without requiring a positive PD-L1 test. In unresectable recurrent or metastatic TNBC, pembrolizumab combinations have a PD-L1 CPS threshold of at least 10. Germline BRCA status can identify PARP inhibitor options in eligible settings. [6][14]
Sentinel nodes assess regional spread. Isolated tumor cells, micrometastases, and larger nodal deposits have different classifications. A positive sentinel node is not automatically stage IIB; anatomic T1N1M0 is stage IIA, while prognostic staging also incorporates grade and biomarkers. Selected patients with limited positive sentinel nodes undergoing breast-conserving therapy and radiation can avoid completion axillary dissection. Match that decision to the trial and guideline eligibility, not to the word “positive” alone. [6]
BRCA1 on chromosome 17 and BRCA2 on chromosome 13 participate in homologous recombination DNA repair. Germline pathogenic variants confer hereditary risk and are different from a tumor's ER or HER2 result. Risk management includes genetic counseling, enhanced breast surveillance, medications where appropriate, and discussion of risk-reducing surgery. Surgery is an informed choice, not an automatic demand at diagnosis of a variant. Risk-reducing salpingo-oophorectomy is generally discussed after childbearing around ages 35 to 40 for BRCA1 and 40 to 45 for BRCA2. It reduces tubo-ovarian risk but does not guarantee a fixed additional percentage reduction in breast cancer risk. Breast MRI cannot substitute for tubo-ovarian risk reduction. [15][17]
Choose the next diagnostic or treatment decision
Case 1
Show answer and explanations for case 1
A. Contrast breast MRI as the routine first study (Why this does not fit)
MRI is not the routine initial test for this uncomplicated new palpable finding.
B. Whole-body PET/CT (Why this does not fit)
There is no established cancer or staging indication, and this does not replace local diagnostic imaging.
C. Screening mammography alone (Why this does not fit)
A symptomatic mass needs diagnostic evaluation, and ultrasound is usually the initial modality at this age.
D. Targeted breast ultrasound (Best answer)
Ultrasound is usually the initial imaging test for a palpable mass in a patient younger than 30.
Takeaway: Use age and the diagnostic question to select the first study.
A. This pattern guarantees cure, independent of the stage at which the tumor is diagnosed (Why this does not fit)
Stage and biology remain important; morphology does not guarantee outcome.
B. Loss of E-cadherin staining must first be demonstrated before this tumor can be reported as having a medullary histologic pattern (Why this does not fit)
Routine morphology can establish histologic pattern; that stain is not a mandatory requirement here.
C. The lymphocytic infiltrate establishes that the epithelial tumor is noninvasive (Why this does not fit)
An immune infiltrate does not change an invasive epithelial tumor into in situ disease.
D. Current classification generally places this in invasive carcinoma of no special type, with a medullary pattern (Best answer)
Modern classification retains the pattern without treating it as a separate universally favorable entity.
Takeaway: Use current classification and avoid treating lymphocytes as a protective capsule.
A. Explain that a pathogenic germline BRCA2 variant and HER2 amplification are different names for the same finding (Why this does not fit)
A germline DNA-repair variant differs from tumor HER2 status.
B. Discuss genetic risk, enhanced breast surveillance, and individualized prevention, including later salpingo-oophorectomy (Best answer)
For BRCA2, risk-reducing salpingo-oophorectomy is generally discussed around ages 40 to 45 after childbearing.
C. Use breast MRI surveillance in place of a separate discussion of tubo-ovarian risk and options for reducing that risk (Why this does not fit)
Breast imaging does not prevent or reliably screen for tubo-ovarian malignancy.
D. Require immediate mastectomy and oophorectomy rather than discussing fertility goals or allowing a choice about preventive surgery (Why this does not fit)
Prevention requires informed decisions and reproductive planning rather than an automatic operation.
Takeaway: Inherited risk care combines prevention, surveillance, and reproductive preferences.
